GraniteShares Launches 2x Leveraged ETFs for ISRG and NBIS Stocks.
ByAinvest
Tuesday, Oct 7, 2025 8:07 am ET2min read
ISRG--
Intuitive Surgical, Inc. (ISRG)
In the latest trading session, Intuitive Surgical, Inc. (ISRG) closed at $452.35, marking a +2.11% move from the previous day. This performance was ahead of the S&P 500's daily gain of 0.01% and the Dow's gain of 0.51%. However, the stock has depreciated by 2.53% over the past month, underperforming the Medical sector's gain of 4.67% and the S&P 500's gain of 4.83% [1].
The company is expected to post an EPS of $1.99 in its upcoming earnings release, indicating an 8.15% growth compared to the equivalent quarter last year. Revenue is projected to reach $2.41 billion, reflecting an 18.2% rise from the equivalent quarter last year [1]. For the entire year, the Zacks Consensus Estimates forecast earnings of $8.17 per share and revenue of $9.78 billion, indicating changes of +11.31% and +17.06%, respectively, compared to the previous year [1].
Intuitive Surgical, Inc. is currently trading with a Forward P/E ratio of 54.23, which is a premium compared to the industry average of 24.05. The PEG ratio of 3.72 also indicates that the stock is trading at a premium to the group, with the industry average PEG ratio being 2.5 [1].
Nebius Group NV (NBIS)
Nebius Group NV (NBIS) has surged over 350% year-to-date in 2025, climbing from around $14 last October to roughly $128 by early October 2025, near all-time highs [2]. The stock's high volatility (beta ~3.5) reflects the explosive growth and risk associated with the company [2].
In September, Nebius inked a 5-year, $17.4 billion AI infrastructure contract with Microsoft, triggering a one-day 44% stock jump to record levels [2]. The deal (expandable to $19.4 billion) gives Microsoft access to Nebius’s high-performance cloud and over 100,000 Nvidia GPUs, underscoring surging AI data center demand [2].
Nebius's Q2 2025 revenue was $105.1 million, up 625% year-over-year (and +106% QoQ) amid an AI computing boom [2]. Though still posting a net loss (EPS –$0.38 vs –$0.41 expected) as it reinvests in growth, analysts project explosive growth ahead – a Nasdaq analysis sees revenue hitting $4.25 billion by 2027 (a 231% CAGR), with positive EBITDA by 2026 [2].
Conclusion
The introduction of these leveraged ETFs by GraniteShares offers investors an opportunity to gain exposure to the short-term movements of ISRG and NBIS. While these ETFs can amplify gains, they also come with the risk of amplifying losses. Investors should carefully consider their risk tolerance and investment objectives before investing in these products.
References
[1] https://finance.yahoo.com/news/intuitive-surgical-inc-isrg-surpasses-215004872.html
[2] https://ts2.tech/en/nebius-groups-meteoric-rise-17b-microsoft-ai-deal-propels-stock-to-new-highs-whats-behind-the-hype/
NBIS--
GraniteShares has launched two new leveraged single-stock ETFs: GraniteShares 2x Long ISRG Daily ETF (ISUL) and GraniteShares 2x Long NBIS Daily ETF (NBIL). These ETFs provide investors with daily leveraged exposure to the stocks of Intuitive Surgical, Inc. (ISRG) and Nebius Group NV (NBIS). The funds aim to replicate the daily percentage change of the respective common stocks, offering investors a way to capitalize on short-term movements in the underlying stocks.
GraniteShares has recently introduced two new leveraged single-stock ETFs: GraniteShares 2x Long ISRG Daily ETF (ISUL) and GraniteShares 2x Long NBIS Daily ETF (NBIL). These ETFs aim to replicate the daily percentage change of the respective common stocks of Intuitive Surgical, Inc. (ISRG) and Nebius Group NV (NBIS), providing investors with a way to capitalize on short-term movements in the underlying stocks.Intuitive Surgical, Inc. (ISRG)
In the latest trading session, Intuitive Surgical, Inc. (ISRG) closed at $452.35, marking a +2.11% move from the previous day. This performance was ahead of the S&P 500's daily gain of 0.01% and the Dow's gain of 0.51%. However, the stock has depreciated by 2.53% over the past month, underperforming the Medical sector's gain of 4.67% and the S&P 500's gain of 4.83% [1].
The company is expected to post an EPS of $1.99 in its upcoming earnings release, indicating an 8.15% growth compared to the equivalent quarter last year. Revenue is projected to reach $2.41 billion, reflecting an 18.2% rise from the equivalent quarter last year [1]. For the entire year, the Zacks Consensus Estimates forecast earnings of $8.17 per share and revenue of $9.78 billion, indicating changes of +11.31% and +17.06%, respectively, compared to the previous year [1].
Intuitive Surgical, Inc. is currently trading with a Forward P/E ratio of 54.23, which is a premium compared to the industry average of 24.05. The PEG ratio of 3.72 also indicates that the stock is trading at a premium to the group, with the industry average PEG ratio being 2.5 [1].
Nebius Group NV (NBIS)
Nebius Group NV (NBIS) has surged over 350% year-to-date in 2025, climbing from around $14 last October to roughly $128 by early October 2025, near all-time highs [2]. The stock's high volatility (beta ~3.5) reflects the explosive growth and risk associated with the company [2].
In September, Nebius inked a 5-year, $17.4 billion AI infrastructure contract with Microsoft, triggering a one-day 44% stock jump to record levels [2]. The deal (expandable to $19.4 billion) gives Microsoft access to Nebius’s high-performance cloud and over 100,000 Nvidia GPUs, underscoring surging AI data center demand [2].
Nebius's Q2 2025 revenue was $105.1 million, up 625% year-over-year (and +106% QoQ) amid an AI computing boom [2]. Though still posting a net loss (EPS –$0.38 vs –$0.41 expected) as it reinvests in growth, analysts project explosive growth ahead – a Nasdaq analysis sees revenue hitting $4.25 billion by 2027 (a 231% CAGR), with positive EBITDA by 2026 [2].
Conclusion
The introduction of these leveraged ETFs by GraniteShares offers investors an opportunity to gain exposure to the short-term movements of ISRG and NBIS. While these ETFs can amplify gains, they also come with the risk of amplifying losses. Investors should carefully consider their risk tolerance and investment objectives before investing in these products.
References
[1] https://finance.yahoo.com/news/intuitive-surgical-inc-isrg-surpasses-215004872.html
[2] https://ts2.tech/en/nebius-groups-meteoric-rise-17b-microsoft-ai-deal-propels-stock-to-new-highs-whats-behind-the-hype/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet